Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
573天前
FTSE 100 Modestly Higher
The UK stock market is modestly higher a little past noon on Tuesday amid expectations of a Ukraine peace deal. Investors are also looking ahead to the Federal Reserve's economic symposium at Jackson Hole, Wyoming, that gets underway on Thursday.
RTTNews
|
5分鐘前
Swiss Franc Rises Against Majors
The Swiss franc strengthened against other major currencies in the European session on Tuesday.
RTTNews
|
24分鐘前
CAC 40 Rises 0.8% As Ukraine Peace Deal Hopes Lift Sentiment
The French market is notably higher on Tuesday as investors pick up stocks amid hopes of a Russia - Ukraine peace deal after U.S. President Donald Trump described his meeting with Ukrainian President Volodymyr Zelenskyy and several other European leaders as "very good".
RTTNews
|
50分鐘前
Home Depot Q2 Profit Down, Misses Street, But Comps Rise; Backs FY25 Outlook
Home Depot Inc. reported Tuesday slightly lower profit in its second quarter, despite higher sales and comparable sales. Meanwhile, Adjusted earnings per share and top line missed market estimates. Further, the company maintained its outlook for fiscal 2025 earnings and sales growth.
RTTNews
|
57分鐘前
Sensex, Nifty Extend Gains On Economic Optimism
Indian shares rose modestly on Tuesday, extending gains from the previous session amid hopes that Prime Minister Modi's recent GST reforms will potentially ease inflation and pave the way for further rate cuts by the Reserve Bank of India (RBI).
RTTNews
|
1小時9分鐘前
DAX Up 0.3% On Ukraine Peace Deal Hopes
German stocks are gaining some ground in positive territory on Tuesday amid hopes of a peace deal between Russia and Ukraine, after U.S. President Donald Trump said his recent meeting with Ukrainian President Volodymyr Zelenskyy and other European leaders progressed well.
RTTNews
|
1小時21分鐘前
European Shares Inch Higher On Hopes Of Russia-Ukraine Peace Deal
European stocks traded higher on Tuesday as investors weighed the possibility of a peace deal between Russia and Ukraine.
RTTNews
|
2小時27分鐘前
